Anavex Life Sciences Corp. (AVXL) Receives Coverage Optimism Rating of 0.24
Headlines about Anavex Life Sciences Corp. (NASDAQ:AVXL) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anavex Life Sciences Corp. earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.5003345358006 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Anavex Life Sciences Corp. (AVXL) Issues Quarterly Earnings Results, Meets Estimates (americanbankingnews.com)
- Anavex Reports Fiscal Third Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Anavex Life Sciences reports 3Q loss (finance.yahoo.com)
- Analyzing Anavex Life Sciences Corp. (NASDAQ:AVXL) and ContraFect Corporation (CFRX) (americanbankingnews.com)
Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 2.54% during mid-day trading on Tuesday, reaching $3.84. The company’s stock had a trading volume of 183,316 shares. The firm’s 50 day moving average is $5.12 and its 200-day moving average is $5.47. The company’s market cap is $158.88 million. Anavex Life Sciences Corp. has a 12-month low of $2.43 and a 12-month high of $6.64.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). Equities analysts anticipate that Anavex Life Sciences Corp. will post ($0.37) earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. Maxim Group set a $15.00 target price on Anavex Life Sciences Corp. and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research raised Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Thursday, June 8th. ValuEngine raised Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Sunday, May 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $11.94.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.